VIB Discovery Sciences•Bio-Incubator •fully integrated screening platform •DD infrastructure...
Transcript of VIB Discovery Sciences•Bio-Incubator •fully integrated screening platform •DD infrastructure...
VIB Discovery Sciences: linking academia to pharma
Maarte Dewilde
Expert Scientist Biologics
Non-confidential
R:255 G:104 30
R:90 G:42 B:130
R:124 G:124 B:124
R:27 G:41 B:68
R:66 G:183 B:186
VIB’s mission
“Excellence in Science and Technology”
“Excellence in Innovation and Business”
R:255 G:104 30
R:90 G:42 B:130
R:124 G:124 B:124
R:27 G:41 B:68
R:66 G:183 B:186
VIB scientists achieve the global top via high impact publications
In Medicine
Times Higher Education Ranking VIB ranks nr 1 on patent citations
• Survey of Times Higher Education in Aug 2015 ranks VIB on 1st place for patent citactions amongst research institutes
R:255 G:104 30
R:90 G:42 B:130
R:124 G:124 B:124
R:27 G:41 B:68
R:66 G:183 B:186
Industrial income 2017: a record year
Total: 28.7 M€
R:255 G:104 30
R:90 G:42 B:130
R:124 G:124 B:124
R:27 G:41 B:68
R:66 G:183 B:186
VIB start-ups – very visible impact
€ € € 1,2B€
total investment
3,9B€ Ablynx
+ Non-Equity Deal-money
AELIN THERAPEUTICS
823 employees
* *
*
*
R:255 G:104 30
R:90 G:42 B:130
R:124 G:124 B:124
R:27 G:41 B:68
R:66 G:183 B:186
Aelin Therapeutics launched with 27M Series A
R:255 G:104 30
R:90 G:42 B:130
R:124 G:124 B:124
R:27 G:41 B:68
R:66 G:183 B:186
Truly innovative, high-impact science is the basis for transformative medicines,...
• “Today’s most transformative medicines exist because of fundamental discoveries that were made without regard to practical outcome and with their relevance to therapeutics only appearing decades later.”
• “….We found that approximately 80% of the medicines… could be traced back to one or several basic discoveries,…”
Source: Nature Drug Discovery Kneller, 2010 Source: Science Translational Medicine, Spector, Harrison & Fishman, 2018
R:255 G:104 30
R:90 G:42 B:130
R:124 G:124 B:124
R:27 G:41 B:68
R:66 G:183 B:186
...but high-impact science alone is not sufficient
Capabilities
Expertise
Infrastructure
Drug discovery projects
Biomedical example Similar in Agro
Return on investment Impact for patients
‘Valley of Death’ = ‘A window of opportunity’
R:255 G:104 30
R:90 G:42 B:130
R:124 G:124 B:124
R:27 G:41 B:68
R:66 G:183 B:186
• Validation of IP
• In-licensing assets
• Combination of IP/assets
• Small equity investment
• Endorsement of VIB’s commitment
Sciences:
• From innovative targets towards novel pharmacology
• Industry-trained discovery team
• Early stage venture fund
• Increase output of novel innovative ventures
VIB intensifies focus on Impact
R:255 G:104 30
R:90 G:42 B:130
R:124 G:124 B:124
R:27 G:41 B:68
R:66 G:183 B:186
• Our mission: Identifying & challenging the true potential of the scientific insights
Starting the journey of innovation
• Achieving Impact: Requires proof-of-concept,...
...and translational research
• Create a synergistic culture of basic science and drug discovery
VIB intensifies focus on Impact
R:255 G:104 30
R:90 G:42 B:130
R:124 G:124 B:124
R:27 G:41 B:68
R:66 G:183 B:186
Project Selection
• Scientific rational & novelty
• Clinical relevance & need
• Status of target validation
• Business & societal impact
• Competitive position & IP landscape
• Target Product Profile
IS IT REAL & SHOULD WE DO IT ?
R:255 G:104 30
R:90 G:42 B:130
R:124 G:124 B:124
R:27 G:41 B:68
R:66 G:183 B:186
Project Selection
• Academic research lab prepared to co-invest
• Target sufficiently validated
• Availability of assays, technologies, tools, in vivo models, ...
• Define screening cascade & assay development
• Key uncertainties in the project
• Co-investing third party
• External funding opportunities
IS IT FEASIBLE ?
R:255 G:104 30
R:90 G:42 B:130
R:124 G:124 B:124
R:27 G:41 B:68
R:66 G:183 B:186
Setup for early drug discovery
• State-of-the-art infrastructure • Bio-Incubator • fully integrated screening platform • DD infrastructure geared towards
Assay Development & Biologics
• VIB Technology Centers – Core Facilities
• Synergistic partners on project-by-project basis
• Industry-experienced Scientists
• + Budget for experimental work
SME
biological
Agro
Commercialisation of VIB Science
De-risk the target • Demonstrate robustness
• Demonstrate druggability
• Demonstrate pharmacological effect
• Develop assays and tools for discovery projects
Generate Proprietary Molecules • Potent and selective Candidate Molecules
• Functional characterisation
• Proof-of-concept In vivo model / human / in planta model
Generate confidence in disease/phenotype association
• Proprietary IP on compounds / biologics
Translational aims
Impact to Society
R:255 G:104 30
R:90 G:42 B:130
R:124 G:124 B:124
R:27 G:41 B:68
R:66 G:183 B:186 Common biology
Next generation Therapeutics
Technology platform
Single therapeutic asset venture
License
Pressure test exciting target biology:
Reproducibility & tractability
Investor-ready proof-of-principle
Co-development on innovative targets
Capital efficient through co-investment or in-kind contributions
External partners
End goal: Creating options for commercialisation
R:255 G:104 30
R:90 G:42 B:130
R:124 G:124 B:124
R:27 G:41 B:68
R:66 G:183 B:186
G-Secretase-stabilizers: An innovative drug discovery partnership to derisk a truly innovative hypothesis on the target validity
Option
VIB Driven Commericalisation
In-kind support: Library (blinded) antibody
Assay development & screening
R:255 G:104 30
R:90 G:42 B:130
R:124 G:124 B:124
R:27 G:41 B:68
R:66 G:183 B:186
BACE1 inhibiting mAb: therapeutic licensing
discovery Benchmarking & deal negotiations
-1 0 -8 -6 -4
-5 0
0
5 0
1 0 0
1 5 0
M B P -C 1 2 5 s w E L IS A
C o n c e n tra tio n
Inh
ibit
ion
(%
)B e n c h m a rk
m A b 1 A 1 1
BBB crossing variant Development and commercialization
R:255 G:104 30
R:90 G:42 B:130
R:124 G:124 B:124
R:27 G:41 B:68
R:66 G:183 B:186
MALT1: therapeutic licensing
Diagnostic Patent Application
Composition of matter IP
Screening Patent
Basic biology series of small molecule inhibitors
R:255 G:104 30
R:90 G:42 B:130
R:124 G:124 B:124
R:27 G:41 B:68
R:66 G:183 B:186
Creating a start-up Company with an exciting pipeline
R:255 G:104 30
R:90 G:42 B:130
R:124 G:124 B:124
R:27 G:41 B:68
R:66 G:183 B:186
Creating an Impact-investor funded start-up Company
+ Subcontractors
CMT-dedicated start-up
company
Patient Impact Biopontis Portfolio Company
Impact investors Charity funders Grant funding
VC funding
+ Patient involvement
Pharma partner involvement
R:255 G:104 30
R:90 G:42 B:130
R:124 G:124 B:124
R:27 G:41 B:68
R:66 G:183 B:186
Target validation Assay devt Hit generation Hit-to-Lead POC Target Discovery
• MALT1 inhibitors for treatment of T- and B-cell inflammation & lymphoma
• Biologicals in Alzheimer’s Disease Licensed
• HINT1 pharmacoperones in type 2 Charcot-Marie Tooth Disease Licensed
VIB’s Drug Discovery pipeline - Partnered
Licensed
• Next generation Immune-Oncology Biologicals
Licensed
• Next generation Immune-Oncology Biologicals
• Next generation Immune-Oncology Biologicals
• Next generation Immune-Oncology Biologicals
• Next generation Immune-Oncology Biologicals
• sdAb’s for Immuno – Prophylaxis/ Therapy in viral infections
• sdAb’s for Immuno – Prophylaxis/ Therapy in viral infections
• Novel target in Alzheimer’s Disease Optioned
Under discussion
• ɣ-Secretase sub-type specific modulators in Alzheimer’s Disease Licensed
CONFIDENTIAL
R:255 G:104 30
R:90 G:42 B:130
R:124 G:124 B:124
R:27 G:41 B:68
R:66 G:183 B:186
• Kinase inhibitor program in allergic asthma
• Metabolism modulators in Immuno-Oncology & IR injury
• Targeting strategies in Asthma / Atopic Dermatitis
• Specific Signaling inhibitors in Oncology
• aggregation pathway targeting
• blocking biologicals in inflammation-associated bone loss
• Immunometabolism targets overcoming Immune Resistance
VIB’s Drug Discovery pipeline - Unpartnered
• N-terminal TAU inhibition program in Alzheimer’s Disease
Target validation Assay devt Hit generation Hit-to-Lead POC Target Discovery
• biologics in aTNF-resistant Rheumatoid Arthritis or OsteoArthritis
• Anti-biofilm molecules as aduvant therapy in Antibiotic treatment
CONFIDENTIAL
• Disease Modifying strategies in CMT: 2 unpublished projects
Corporate VC Diligence
VC Diligence
• BBB crossing technology development
R:255 G:104 30
R:90 G:42 B:130
R:124 G:124 B:124
R:27 G:41 B:68
R:66 G:183 B:186
R:255 G:104 30
R:90 G:42 B:130
R:124 G:124 B:124
R:27 G:41 B:68
R:66 G:183 B:186
VIB start-up portfolio – realized
° 1996, RNAi company -> agro IPO 2005 2012 Syngenta acquisition ($522M) R&D center in Flanders
° 1998, 2006 BASF acquisition (96M Euro) R&D center in Flanders (2016)
° 2001, 2007 Euronext IPO 2017 NASDAQ IPO 3,9B Euro offer by Sanofi (2018) Operations in Gent (#490)
° 2006 Live biotherapeutics 2015 acquisition by Intrexon ($60M) Intrexon Actobiotics unit in Gent (#33)
°2006 Diagnostics / proteomics 2014 acquisition by Biocartis Mycartis spin-out Operations in Gent (#43)
°2011 Diagnostics / NGS kits 2016 acquisition by Agilent (68M Euro) Multiplicom subsidiary in BE
°2011 ; CMO Acquired by Amatsi, then EuroFins Operations in Gent / GMP facility
R:255 G:104 30
R:90 G:42 B:130
R:124 G:124 B:124
R:27 G:41 B:68
R:66 G:183 B:186
VIB start-up portfolio - active
°2013 Agrobodies for crop protection Series B of 11M Euro led by Sofinnova
°2015 Clinical asset TB-403 for medulloblastoma Pipeline of IO assets Thrombogenics – VIB JV
°2015 Reprogramming the immune system in IO and beyond Genome scale SM discovery US-BE transatlantic structure
°2015 VIB affiliated venture fund 75M Euro Invests in agro, diagnostics, biopharmaceutical,
°2016 Superior micro-organisms for sustainable agriculture 7,7M Euro Series A
°2015 Superior GPCR drug discovery Confobodies as stabilizing tools for GPCRs 6,7M Euro Series A round deals with Roche ; Lundbeck
°2017 Novel therapeutic modality based on protein aggregation Anti-infectives / oncology 27M Series A round LSP; NVF; PMV; BIVF; Fund+
°2015 Superior industrial yeast strains for bio-based economy Belgian – Brazilian biotech Launched with 6,25M Euro